

COMPANY COMPILED CONSENSUS FORECAST – 23 DECEMBER 2022

		Q4/2022				# estimates
		Consensus	High	Low		
Group sales/revenue	in million €	334,8	351,0	315,3	10	
Group sales/revenue growth	% y-o-y	16,2	21,9	9,5	10	
Non-Rx sales growth	% y-o-y	17,4	23,6	10,5	9	
Adj. EBITDA	in million €	0,4	6,0	-3,8	9	
Adj. EBITDA margin	%	0,1	1,9	-1,1	9	
<i>Non-Rx and adjusted EBITDA numbers are for ongoing business as at the time of issuing the guidance in March 2022</i>						

		2022				# estimates
		Consensus	High	Low		
Group sales/revenue	in million €	1211,2	1228,0	1191,9	10	
Group sales/revenue growth	% y-o-y	14,2	15,8	12,4	10	
Non-Rx sales growth	% y-o-y	17,8	19,5	15,9	9	
Adj. EBITDA	in million €	-6,8	-1,0	-13,0	9	
Adj. EBITDA margin	%	-0,6	-0,1	-1,1	9	
<i>Non-Rx and adjusted EBITDA numbers are for ongoing business as at the time of issuing the guidance in March 2022</i>						

Disclaimer:

Shop Apotheke Europe N.V. (further: "SAE") has collated the estimates of analysts who regularly analyze SAE, submitted during the period 23/09/2022 up to 30/09/2022 using a standard template. This consensus is provided by SAE for information purposes only. Estimates, forecasts, and recommendations of the analysts and the consensus derived therefrom do not represent estimates, forecasts, or recommendations of SAE, but those of the analysts only. Neither SAE nor its Managing Board or subsidiaries have reviewed the analyst estimates and, therefore, do not endorse or concur with the consensus or any underlying research or assumptions in any way. SAE makes no express or implied warranty or representation as to the accuracy, reasonableness, completeness or likelihood of achieving the consensus figures, including updates, revisions, or supplements thereto. The consensus is based on current views and assumptions and involves known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those included in such research, assumptions or projections. SAE does not adopt the consensus as its own. Nothing in this consensus constitutes investment advice or a solicitation to buy, hold or sell securities or other financial instruments of SAE, or to rely on any of the information included in this consensus. It should be noted that forecasts are by definition forward looking and are therefore subject to risks and uncertainties that may materially affect eventual results. SAE does not accept any liability for reliance upon, or actions taken based on, any of the information set out in this consensus.